Matched Proteinase + Inhibitor Antibody Pairs

Proteinase activity in vivo is rarely studied in isolation. Each proteolytic enzyme is counterbalanced by an endogenous inhibitor, and the net activity — not the absolute abundance of the protease — determines physiological outcome. Measuring MMP-9 protein without measuring TIMP-1 or TIMP-2 provides only half the information needed to understand extracellular matrix turnover. Studying cathepsin B expression without monitoring cystatin C misses the regulatory context that defines lysosomal proteolysis. Since 1994, Triple Point Biologics has maintained a unique catalog position: we produce rabbit polyclonal antibodies for both the protease and the inhibitor in every major proteolytic axis, allowing researchers to quantify stoichiometric balance rather than isolated enzyme abundance.

The matched-pair principle — why studying both halves matters

Proteolytic systems function as dynamic equilibria. The ratio of active protease to free inhibitor determines net proteolytic capacity in tissue lysates, conditioned media, and biofluids. In cancer invasion models, elevated MMP-2 is only prognostically relevant when TIMP-2 levels are insufficient to neutralize it. In neurodegenerative disease, cathepsin activity reflects not only cathepsin B or L expression, but also the local concentration of cystatin B and cystatin C. Calpain-mediated cytoskeletal remodeling depends on the stoichiometry between μ-calpain or m-calpain and their common inhibitor, calpastatin.

Quantitative Western blotting or multiplex immunoassays that measure both protease and inhibitor allow calculation of molar ratios and estimation of free (uninhibited) enzyme. This approach has been validated in fibrosis research, where MMP/TIMP imbalance predicts collagen accumulation better than MMP expression alone, and in Alzheimer's disease studies, where cathepsin/cystatin ratios correlate with amyloid plaque burden. Matched-pair antibody panels enable this type of quantitative proteolytic balance analysis.

MMP / TIMP — the canonical matched system

Matrix metalloproteinases and tissue inhibitors of metalloproteinases form the prototypical matched-pair system. The four human TIMPs (TIMP-1, TIMP-2, TIMP-3, TIMP-4) are broad-spectrum MMP inhibitors with overlapping but distinct specificities. TIMP-1 preferentially inhibits MMP-9 and MMP-1, while TIMP-2 forms stable complexes with MMP-2 and regulates MT1-MMP activation at the cell surface. TIMP-3 is ECM-associated and uniquely inhibits ADAM and ADAMTS proteases in addition to MMPs. TIMP-4 shows cardiac-enriched expression and modulates MMP-2 and MMP-9 in myocardial remodeling.

Triple Point Biologics produces validated rabbit polyclonal antibodies against all four TIMPs: Anti-TIMP-1, Anti-TIMP-2, Anti-TIMP-3, and Anti-TIMP-4. These antibodies are validated for Western blot, enabling detection of both latent and active TIMP forms. When paired with the corresponding MMP antibodies from our catalog, researchers can assess proteolytic balance in tumor microenvironments, fibrotic tissues, and vascular remodeling models.

What's the difference between studying MMPs alone vs MMP/TIMP balance?

Measuring MMP expression or activity in isolation does not predict net proteolytic output. TIMPs bind MMPs in 1:1 stoichiometry, and excess TIMP can completely neutralize elevated MMP levels. In wound healing and cancer, the MMP/TIMP ratio is a better predictor of matrix degradation, invasion, and metastasis than MMP levels alone. Quantifying both components allows calculation of free (active) enzyme and provides mechanistic insight into why proteolysis occurs or fails to occur despite protease upregulation. Antibody-based quantification of matched pairs is essential for this analysis.

Beyond the classical TIMPs, the membrane-anchored inhibitor RECK regulates MMP-2, MMP-9, and MT1-MMP at the cell surface and has emerged as a key suppressor of tumor invasion and angiogenesis.

Cathepsin / Cystatin — lysosomal proteinase regulation

Cathepsins are lysosomal cysteine and aspartyl proteases critical for intracellular protein degradation, antigen processing, and — when secreted or released — extracellular matrix remodeling. Cathepsin B, L, S, K, and others are tightly regulated by the cystatin superfamily of inhibitors. Cystatins are divided into three main types: Type 1 (intracellular, stefins), Type 2 (extracellular, classical cystatins), and Type 3 (kininogens). The most studied cathepsin inhibitors in human disease are cystatin A (stefin A), cystatin B (stefin B), and cystatin C.

Cystatin B mutations cause Unverricht-Lundborg disease, a progressive myoclonic epilepsy linked to uncontrolled cathepsin activity in neurons. Cystatin C is secreted and functions as a pan-cathepsin inhibitor in plasma and cerebrospinal fluid; reduced CSF cystatin C has been reported in Alzheimer's disease and correlates with increased cathepsin-mediated tau cleavage. Cystatin M (cystatin E) is epithelial-restricted and regulates cathepsin V and L in skin and keratinocytes.

TPB produces a full panel of cystatin antibodies: Anti-Cystatin-A, Anti-Cystatin-B, Anti-Cystatin-C, Anti-Cystatin-D, Anti-Cystatin-F, Anti-Cystatin-M, and Anti-Cystatin-SA. These antibodies allow matched-pair studies with our cathepsin antibody line, enabling analysis of cathepsin/cystatin stoichiometry in neurodegeneration, cancer, and inflammatory disease models.

How does cystatin C regulate cathepsin activity?

Cystatin C is a secreted, 13 kDa inhibitor that binds cathepsins B, H, L, and S with high affinity (Ki in the low nanomolar range). It is constitutively expressed in most tissues and is the predominant extracellular cathepsin inhibitor in blood and cerebrospinal fluid. Cystatin C prevents aberrant extracellular proteolysis by neutralizing cathepsins released during cell damage or secreted by tumor cells. In neurodegenerative disease, reduced cystatin C expression or cleavage by other proteases leads to elevated cathepsin activity, contributing to neuronal death and protein aggregation. Measuring cystatin C alongside cathepsin levels provides a functional readout of net proteolytic activity.

Why do researchers study proteases and their inhibitors together?

Protease activity in tissue is determined not by enzyme expression alone, but by the local balance between active protease and endogenous inhibitors. A tissue may express high levels of a protease, yet show minimal proteolytic activity due to saturating inhibitor concentrations. Conversely, modest protease upregulation paired with inhibitor depletion can produce severe pathology. Quantifying both the protease and its cognate inhibitor allows calculation of the free enzyme fraction and reveals whether proteolytic dysregulation results from enzyme overexpression, inhibitor deficiency, or both. This dual measurement is critical for mechanistic studies and for identifying therapeutic targets.

Calpain / Calpastatin — calcium-dependent proteolysis control

Calpains are calcium-activated cysteine proteases that cleave cytoskeletal proteins, signaling molecules, and transcription factors. The ubiquitous isoforms — μ-calpain (CAPN1) and m-calpain (CAPN2) — require micromolar and millimolar calcium, respectively, and are activated during excitotoxicity, ischemia, and mechanical injury. Calpastatin is the sole endogenous inhibitor of calpains, binding in a calcium-dependent manner to block the active site.

Calpain/calpastatin imbalance is implicated in neuronal injury, muscular dystrophy, cardiac ischemia-reperfusion injury, and cancer cell motility. In traumatic brain injury models, calpain activation exceeds calpastatin upregulation, leading to spectrin breakdown and synaptic dysfunction. In Duchenne muscular dystrophy, calcium overload and inadequate calpastatin expression drive calpain-mediated myofibrillar degradation.

The Anti-Calpastatin Antibody from TPB allows quantification of this critical inhibitor alongside calpain activity measurements or calpain-specific antibodies. Calpastatin exists in multiple splice variants and tissue isoforms; our antibody is raised against conserved inhibitory domains and recognizes the major forms in human, mouse, and rat tissues.

Why is calpastatin important when studying calpains?

Calpastatin is the only known endogenous inhibitor specific to calpains. Its expression level and subcellular localization determine the threshold for calpain activation and the duration of calpain-mediated proteolysis. In pathological conditions such as stroke, traumatic brain injury, or muscular dystrophy, calpain activity often exceeds calpastatin capacity, leading to uncontrolled cytoskeletal breakdown and cell death. Measuring calpastatin allows researchers to determine whether calpain-mediated pathology results from enzyme overactivation, inhibitor depletion, or a mismatch in their stoichiometry. This is particularly important when evaluating calpain inhibitors as therapeutics, since baseline calpastatin levels influence drug efficacy.

TMPRSS / HAI — pericellular protease regulation

Type II transmembrane serine proteases (TTSPs), including TMPRSS2, TMPRSS4, and matriptase, regulate epithelial barrier function, prostasin activation, and viral entry (notably SARS-CoV-2 spike protein priming). These membrane-anchored proteases are tightly controlled by hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2), Kunitz-type serine protease inhibitors that form covalent complexes with TTSPs at the cell surface.

HAI-1 (encoded by SPINT1) is essential for epithelial integrity; HAI-1 knockout mice are embryonic lethal due to uncontrolled matriptase activity. HAI-2 (SPINT2) cooperates with HAI-1 and is frequently downregulated in epithelial cancers, correlating with increased invasiveness. The TMPRSS/HAI axis is relevant not only in cancer and development, but also in infectious disease; TMPRSS2 inhibition or HAI upregulation can block influenza and coronavirus entry.

TPB offers validated rabbit polyclonal antibodies against both inhibitors: Anti-HAI-1 and Anti-HAI-2. When combined with TMPRSS antibodies, these enable studies of pericellular protease regulation in epithelial cells, tumor cell lines, and viral infection models.

Serine proteases / Serpins — the largest matched family

Serine protease inhibitors (serpins) comprise the largest and most diverse family of protease inhibitors in humans, with 36 genes encoding circulating, intracellular, and extracellular inhibitors. Serpins inhibit serine proteases via a suicide-substrate mechanism, forming stable covalent complexes. Key serpin subfamilies include:

• SERPINA (clade A): Includes alpha-1-antitrypsin (SERPINA1), alpha-1-antichymotrypsin (SERPINA3), and neuroserpin. SERPINA1 inhibits neutrophil elastase; deficiency causes emphysema and liver cirrhosis.
• SERPINB (clade B): Intracellular serpins that regulate granzymes, cathepsin G, and other proteases. Examples include SERPINB1 (leukocyte elastase inhibitor) and SERPINB9 (granzyme B inhibitor).
• Neuroserpin: A neuronal serpin that inhibits tissue plasminogen activator (tPA) and is mutated in familial encephalopathy with neuroserpin inclusion bodies (FENIB).

TPB provides the most extensive serpin antibody panel available from a single source, including Anti-Serpin-A2, Anti-Serpin-A3, Anti-Serpin-A5, Anti-Serpin-A8 (Angiotensinogen), and the full SERPINB family from SERPINB1 through SERPINB13. Additional non-serpin serine protease inhibitors include elafin and SLPI, both of which regulate neutrophil elastase and proteinase-3 in the lung and skin.

This breadth allows construction of multiplex panels for studying protease/inhibitor balance in inflammation, coagulation, fibrinolysis, and immune cell cytotoxicity. For example, granzyme B activity in cytotoxic T lymphocytes can be analyzed alongside SERPINB9 to determine whether tumor cells escape immune killing via inhibitor upregulation.

Working with matched-pair panels — what to measure and why

Practical application of matched-pair antibodies requires coordination of sample preparation, assay format, and data interpretation. Key considerations include:

• Stoichiometric quantification: Use recombinant protein standards or purified protease/inhibitor complexes to generate standard curves in the linear range. Report concentrations in molar units to enable ratio calculation.
• Complex vs. free forms: Proteases and inhibitors may exist as free enzyme, free inhibitor, or covalent complex. Western blot under reducing vs. non-reducing conditions can distinguish these forms; some complexes (e.g., serpin-protease) are SDS-stable and migrate as high-molecular-weight bands.
• Active site titration: Antibody-based measurement of total protein does not distinguish zymogen from active enzyme. Pair immunodetection with activity-based probes or active-site titrants when functional activity is the endpoint.
• Tissue and fluid selection: Some inhibitors (e.g., cystatin C, alpha-1-antitrypsin) are abundant in plasma; others (e.g., calpastatin, SERPINB9) are intracellular. Matched-pair analysis requires selecting the compartment where protease and inhibitor colocalize.

Multiplex Western blotting or Luminex-based immunoassays with matched-pair antibodies enable high-throughput profiling of proteolytic balance across disease models, drug treatments, or patient cohorts.

TPB's unique position — both halves of every major axis

Most antibody suppliers offer partial coverage of protease-inhibitor systems: MMP antibodies without complete TIMP panels, cathepsin antibodies without the full cystatin family, or serpin antibodies limited to the most common clades. Triple Point Biologics has maintained a unique focus since 1994: producing rabbit polyclonal antibodies for both the protease and the inhibitor in every major proteolytic system. This catalog structure reflects the biological reality that protease function is meaningless without its regulatory context.

Our rabbit polyclonal antibodies are raised against recombinant human proteins or synthetic peptides corresponding to non-conserved regions, minimizing cross-reactivity within closely related family members (e.g., distinguishing TIMP-1 from TIMP-2, or SERPINB1 from SERPINB6). Antibodies are affinity-purified and validated for Western blot; predicted cross-reactivity with mouse and rat orthologs is based on sequence homology and, where tested, confirmed by blot.

This breadth is particularly valuable for researchers building multiplex panels, comparing proteolytic balance across tissue types, or screening for inhibitor deficiencies in disease models. Instead of sourcing antibodies from multiple vendors — each with different validation standards, lot-to-lot variability, and epitope coverage — researchers can assemble matched-pair panels from a single, consistent source.

Practical antibody panels for inhibitor-pair studies

Below are representative matched-pair antibody panels for common research applications:

• Cancer invasion and metastasis: MMP-2, MMT1-MMP, MMP-9, TIMP-2, TIMP-1, RECK. Quantify in tumor lysates and conditioned media to assess net collagenolytic and gelatinolytic capacity.
• Neurodegeneration: Cathepsin B, cathepsin L, calpain-1, calpain-2, cystatin B, cystatin C, calpastatin. Measure in brain homogenates or CSF to evaluate lysosomal and calcium-dependent proteolysis.
• Acute lung injury and ARDS: Neutrophil elastase, proteinase-3, MMP-9, SERPINA1, elafin, SLPI, TIMP-1. Profile in bronchoalveolar lavage fluid.
• Viral infection (SARS-CoV-2, influenza): TMPRSS2, HAI-1, HAI-2. Analyze in airway epithelial cells or lung tissue to assess protease-dependent viral entry.
• Immune evasion: Granzyme B, SERPINB9; cathepsin C, cystatin F. Quantify in tumor-infiltrating lymphocytes or tumor cells to determine inhibitor-mediated resistance to cytotoxic killing.

Each panel combines protease and inhibitor antibodies to provide a systems-level view of proteolytic regulation, rather than isolated snapshots of enzyme expression.

References

1. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55-71. PMID: 20080133
2. Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 2012;1824(1):68-88. PMID: 22024571
3. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003;83(3):731-801. PMID: 12843408
4. Szabo R, Bugge TH. Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu Rev Cell Dev Biol. 2011;27:213-235. PMID: 21721945
5. Law RH, Zhang Q, McGowan S, et al. An overview of the serpin superfamily. Genome Biol. 2006;7(5):216. PMID: 16737556
6. Sivaparvathi M, Sawaya R, Wang SW, et al. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis. 1995;13(1):49-56. PMID: 7820955